Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00842985 · ClinicalTrials.gov registry record · Early Phase 1

Dronabinol Interactions With Cognitive Enhancing Drug in Humans

A Early Phase 1 study, sponsored by Yale University.

Completed
Registry status
Early Phase 1
Development phase
53
Enrollment target

NCT00842985 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 53 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00842985, a Early Phase 1 study, has completed, sponsored by Yale University.

COMPLETED
Registry status
Early Phase 1
Development phase
53 participants
Enrollment target

Study Summary

Marijuana use is a major problem among veterans and non-veterans. A patient's use of marijuana while engaged in psychotherapy treatment may affect their memory and, therefore, limit their ability to benefit from treatment. This study is designed to test a new pharmacotherapy, modafinil, which has the potential to improve memory functioning in marijuana using individuals. We hypothesize that modafinil treatment will decrease ratings of drug liking and improve cognitive measures, especially episodic memory.

Interventions

  • DRUG drug condition

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2008-09
Est. Completion 2009-10
Phase Early Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT00842985

The ClinicalTrials.gov registry entry for NCT00842985 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which drug condition is the first listed.

NCT00842985 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00842985 about?

NCT00842985 is a clinical study titled "Dronabinol Interactions With Cognitive Enhancing Drug in Humans". Marijuana use is a major problem among veterans and non-veterans. A patient's use of marijuana while engaged in psychotherapy treatment may affect their memory and, therefore, limit their ability to benefit from treatment. This study is designed to test a new pharmacotherapy, modafinil, which has th...

What is the current status of trial NCT00842985?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 53 participants. The study started on 2008-09. Estimated completion is 2009-10.

What interventions are being tested in trial NCT00842985?

The interventions under investigation include: drug condition (DRUG).

Who is sponsoring clinical trial NCT00842985?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.